+0.0
net board stance
what this means
83.85
+3.1% · close 2026-11-06
-4% / -12% / +10%
1m / 3m / 12m
+20%
vs SPY since 2025-08-01
38%
of 52w range · -23.2% off high
0/2
hit rate as primary · vs SPY -31
Where All-In Alpha stands — 0 live ideas
No active idea holds this ticker. Anything below is history.
Where the winds are blowing
NET BOARD STANCE, LAST 60 EPISODES —
rising = the besties are building this position, falling = abandoning it. From the
conviction ledger; an idea counts from birth until its window closes. Dots mark episodes
where this ticker's ideas were actually mentioned; a dashed stretch is silence.
Last mention E228 · silent for 67 episodes.
PRICE VS SPY OVER THE SAME WINDOW, % — did the
talk lead the tape or follow it?
Who's pushing which way
each voice's net push ON THIS TICKER — their most recent stance per idea × that idea's direction ON THIS TICKER × strength, so supporting a bearish idea pushes down, unless this ticker is listed as the other side of it. Not conviction (that lives on the idea); this is direction of travel per person. what w= means
Track record on CVS
As a PRIMARY play the besties are 0 hit / 1 partial / 1 miss over 2 closed windows — credit 0.25, average vs SPY -31.3. Adjacent plays are listed but never scored.
| idea | call | play | result | return | vs SPY | scored |
|---|---|---|---|---|---|---|
| 📈 PBM margin model breaks on drug-price transparency | ▼ SHORT | primary | WRONG | -28.8% | -48.1 | 2025-10-03 |
| 🏛️ PBMs, not pharma, are the real drug-price target | ▼ SHORT | primary | HALF | +13.9% | -14.4 | 2024-05-19 |
The tape — what was actually said
every capture on any idea holding CVS, newest first · quotes verbatim, timestamps deep-link into the episode
Friedberg
support ×3
▼ on
📈 PBM margin model breaks on drug-price transparency
E228 · 2025-05-17
▶ 1:33:36
There's three major PBMs, CVS Caremark, Express Scripts and Optum RX. These three companies make on average approximately three bucks in operating profit per prescription claim processed. They make money in markups.
Chamath
support ×2
▼ on
📈 PBM margin model breaks on drug-price transparency
E228 · 2025-05-17
▶ 1:29:04
So there's a lot of other organizations in this value chain that kind of eat out of that dollar before it gets to the sense that goes to pharma. And so it's important to make sure we don't overlook those. The biggest ones being the PBMs.
Mark Cuban
support ×3
▼ on
📈 PBM margin model breaks on drug-price transparency
E198 · 2024-10-03
▶ 1:43:45
And by working, by requiring transparency in all contracts, signed by anybody anywhere in terms of pricing, you are going to see the same impact on across-the-board pricing of a decrease of 30-40 percent. And so all that is going to reduce out-of-pocket spending for everybody, reduce government spending for everybody, and have a net positive impact.
Chamath
support ×2
▼ on
🏛️ PBMs, not pharma, are the real drug-price target
E129 · 2023-05-19
▶ 1:01:23
So to your point, Sacks, the FTC has been worried that what Friedberg said has been happening, but the real sort of middlemen manipulator in this market are the pharmacy benefit managers. And so this week, she actually issued compulsory orders to the PBMs and said, turn over all your business records to me. I'm going to look into them. That makes a ton of sense.